Boston Scientific shares slide on cautious 2026 revenue forecast

Core Viewpoint - Boston Scientific Corp's forecast for modest revenue growth and profit in 2026 fell short of Wall Street expectations, leading to a significant drop in share price despite a strong fourth-quarter performance [1][2]. Group 1: Financial Performance - The company reported adjusted earnings of 80 cents per share, exceeding the consensus estimate of 78 cents [3]. - Revenue for the fourth quarter was $5.29 billion, slightly above forecasts of $5.28 billion [3]. - For the first quarter of 2026, Boston Scientific anticipates adjusted earnings of 78 to 80 cents per share, compared to the analyst consensus of 79 cents [3]. Group 2: Future Outlook - Boston Scientific projected adjusted earnings per share for 2026 to be between $3.43 and $3.49, with a midpoint of $3.46, which is below the average analyst estimate of $3.47 [1][2]. - The company expects organic revenue growth of 10% to 11% for 2026, a decrease from the 15.8% organic growth recorded in 2025 [2]. - The subdued outlook is influenced by the upcoming integration of its $14.5 billion acquisition of Penumbra, announced last month [2].